Cantor Fitzgerald Reduces Earnings Estimates for Exagen

Exagen Inc. (NASDAQ:XGN) – Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Exagen in a research report issued on Thursday, May 15th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($0.61) per share for the year, down from their prior estimate of ($0.59). Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share.

A number of other equities analysts have also commented on XGN. Canaccord Genuity Group boosted their price target on shares of Exagen from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Tuesday, May 13th. UBS Group reissued an “overweight” rating on shares of Exagen in a report on Thursday. William Blair reaffirmed an “outperform” rating on shares of Exagen in a research note on Wednesday, March 12th. Finally, BTIG Research reiterated a “buy” rating on shares of Exagen in a research report on Wednesday, May 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Exagen currently has a consensus rating of “Buy” and a consensus target price of $7.50.

Exagen Stock Up 5.3%

XGN opened at $6.33 on Monday. The firm has a market cap of $134.83 million, a price-to-earnings ratio of -6.73 and a beta of 1.50. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The firm’s 50-day simple moving average is $4.87 and its 200-day simple moving average is $4.26. Exagen has a twelve month low of $1.71 and a twelve month high of $7.20.

Exagen (NASDAQ:XGN) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20). The firm had revenue of $15.50 million during the quarter, compared to analyst estimates of $14.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same period in the prior year, the company posted ($0.19) earnings per share.

Hedge Funds Weigh In On Exagen

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Toronto Dominion Bank acquired a new stake in Exagen during the 4th quarter worth approximately $3,655,000. Driehaus Capital Management LLC acquired a new stake in Exagen during the fourth quarter worth about $1,716,000. Marshall Wace LLP acquired a new stake in shares of Exagen in the 4th quarter valued at $66,000. Kennedy Capital Management LLC boosted its stake in Exagen by 8.8% in the fourth quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company’s stock valued at $756,000 after buying an additional 14,920 shares in the last quarter. Finally, Palumbo Wealth Management LLC grew its holdings in shares of Exagen by 14.4% during the 1st quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company’s stock valued at $356,000 after purchasing an additional 12,501 shares during the last quarter. 75.25% of the stock is owned by institutional investors.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).